- Home
- YQ vs RLMD Comparison
YQ vs RLMD Comparison
Compare YQ & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- RLMD
- Stock Information
- Founded
- YQ 2012
- RLMD 2004
- Country
- YQ China
- RLMD United States
- Employees
- YQ N/A
- RLMD N/A
- Industry
- YQ Other Consumer Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- YQ Real Estate
- RLMD Health Care
- Exchange
- YQ Nasdaq
- RLMD Nasdaq
- Market Cap
- YQ 19.4M
- RLMD 20.3M
- IPO Year
- YQ 2020
- RLMD N/A
- Fundamental
- Price
- YQ $1.90
- RLMD $0.59
- Analyst Decision
- YQ
- RLMD Buy
- Analyst Count
- YQ 0
- RLMD 3
- Target Price
- YQ N/A
- RLMD $5.00
- AVG Volume (30 Days)
- YQ 44.6K
- RLMD 206.5K
- Earning Date
- YQ 09-03-2025
- RLMD 08-07-2025
- Dividend Yield
- YQ N/A
- RLMD N/A
- EPS Growth
- YQ N/A
- RLMD N/A
- EPS
- YQ N/A
- RLMD N/A
- Revenue
- YQ $25,546,613.00
- RLMD N/A
- Revenue This Year
- YQ N/A
- RLMD N/A
- Revenue Next Year
- YQ N/A
- RLMD N/A
- P/E Ratio
- YQ N/A
- RLMD N/A
- Revenue Growth
- YQ N/A
- RLMD N/A
- 52 Week Low
- YQ $1.26
- RLMD $0.24
- 52 Week High
- YQ $3.19
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- YQ 35.80
- RLMD 44.70
- Support Level
- YQ $1.85
- RLMD $0.60
- Resistance Level
- YQ $2.23
- RLMD $0.67
- Average True Range (ATR)
- YQ 0.14
- RLMD 0.06
- MACD
- YQ -0.05
- RLMD -0.00
- Stochastic Oscillator
- YQ 7.94
- RLMD 16.42
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.